Plasma PTX3 measurements may be noninvasive and appear to show promise as a means to differentiate NASH from non-NASH patients, and as a clinical marker of the severity of liver fibrosis in NASH patients. Here, PTX3 is linked to metabolic dysfunction-associated steatohepatitis.